Journal article
Associations of context-specific sitting time with markers of cardiometabolic risk in Australian adults
PC Dempsey, NT Hadgraft, EAH Winkler, BK Clark, MP Buman, PA Gardiner, N Owen, BM Lynch, DW Dunstan
International Journal of Behavioral Nutrition and Physical Activity | BMC | Published : 2018
Abstract
Background: High volumes of sitting time are associated with an elevated risk of type 2 diabetes and cardiovascular disease, and with adverse cardiometabolic risk profiles. However, previous studies have predominately evaluated only total sitting or television (TV) viewing time, limiting inferences about the specific cardiometabolic health impacts of sitting accumulated in different contexts. We examined associations of sitting time in four contexts with cardiometabolic risk biomarkers in Australian adults. Methods: Participants (n = 3429; mean ± SD age 58 ± 10 years) were adults without clinically diagnosed diabetes or cardiovascular disease from the 2011-2012 Australian Diabetes, Obesity a..
View full abstractGrants
Awarded by State Government of Victoria
Funding Acknowledgements
The AusDiab study was co-coordinated by the Baker Heart and Diabetes Institute and sponsored by National Health and Medical Research Council (NHMRC grants: #233200, #1007544); Australian Government Department of Health and Ageing; Abbott Australasia Pty Ltd.; Alphapharm Pty Ltd.; Amgen Australia; AstraZeneca; Bristol-Myers Squibb; City Health Centre-Diabetes Service-Canberra; Department of Health and Community Services, Northern Territory; Department of Health and Human Services, Tasmania; Department of Health, New South Wales; Department of Health, Western Australia; Department of Health, South Australia; Department of Human Services, Victoria; Diabetes Australia; Diabetes Australia Northern Territory; Eli Lilly Australia; Estate of the Late Edward Wilson; GlaxoSmithKline; Jack Brockhoff Foundation; Janssen-Cilag; Kidney Health Australia; Marian & FH Flack Trust; Menzies Research Institute; Merck Sharp & Dohme; Novartis Pharmaceuticals; Novo Nordisk Pharmaceuticals; Pfizer Pty Ltd.; Pratt Foundation; Queensland Health; Roche Diagnostics Australia; Royal Prince Alfred Hospital, Sydney; Sanofi Aventis; and sanofi-synthelabo. The AusDiab study acknowledges the support and assistance given by: K. Anstey, B. Atkins, B. Balkau, E. Barr, A. Cameron, S. Chadban, M. de Courten, A. Kavanagh, D. Magliano, S. Murray, K. Polking-horne, J. Shaw, T. Welborn, P. Zimmet and all the study participants. PCD and BC are supported by National Health and Medical Research Council of Australia (NHMRC) Early Career Fellowships (#1142685 & #1107168). PG is supported by a NHMRC Dementia Research Development Fellowship and Australian Research Council (#110331). BL is supported by a Fellowship from the National Breast Cancer Foundation (ECF-15-012). NO and DD are supported by NHMRC Senior Principal Research Fellowships (#1003960 & #1078360) and by the Victorian Government's Operational Infrastructure Support program. The funders of this study had no role in the data analysis or interpretation of the results.